News

Johnson & Johnson’s Darzalex with Halozyme’s Enhanze granted EU approval
Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received European Commission approval for an ...
Seeking Alpha3d
J&J, Halozyme get EU nod for Darzalex SC to treat multiple myeloma
Halozyme Therapeutics (NASDAQ:HALO) announced on Wednesday that the European Commission has approved an injectable combo regimen of Darzalex, the antibody therapy of Johnson & Johnson (NYSE:JNJ ...
ETF Daily News5d
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by CIBC Private Wealth Group LLC
Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $66.00. The stock has a market cap of $7.33 billion, a price-to-earnings ratio of 17.30, a PEG ratio of 0.42 and a ...
Seeking Alpha5d
J&J, Halozyme win EU nod for injectable Rybrevant in lung cancer
Halozyme Therapeutics (NASDAQ:HALO) announced Monday that the European Commission has approved an injectable version of Johnson & Johnson’s (NYSE:JNJ) antitumor agent Rybrevant for certain ...
Business Insider5d
EC approves subcutaneous RYBREVANT in combination with LAZCLUZE
Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, has received European Commission marketing authorization of the subcutaneous ...
Nasdaq3d
Halozyme Reports EC Approval For Indication Extension Of DARZALEX Co-formulated With ENHANZE
(RTTNews) - Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission approval for an indication extension of DARZALEX ...
ETF Daily News6d
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by California Public Employees Retirement System
Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $66.00. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.
Investing5d
EC approves new lung cancer treatment using Halozyme technology
SAN DIEGO - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a $7.36 billion market cap biopharmaceutical company with impressive gross margins of 76.5%, has announced the European Commission’s ...
Investing5d
EC approves new lung cancer treatment using Halozyme technology
SAN DIEGO - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a $7.36 billion market cap biopharmaceutical company with impressive gross margins of 76.5%, has announced the European Commission’s ...
Nasdaq5d
Halozyme Says EC Approved Subcutaneous Rybrevant For Advanced EGFR-Mutated NSCLC
(RTTNews) - Halozyme Therapeutics, Inc. (HALO) Monday said that Janssen-Cilag International NV, a Johnson & Johnson company, has received marketing authorization from the European Commission (EC ...
pharmaphorum5d
Halozyme abandons its €2bn pursuit of Evotec
US biotech Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been "unwilling to engage with us to explore a potential combination." Halozyme made ...